Chiusura precedente | 41,12 |
Aperto | 40,63 |
Denaro | 36,78 x 100 |
Lettera | 37,53 x 100 |
Min-Max giorno | 36,09 - 40,80 |
Intervallo di 52 settimane | 3,03 - 49,87 |
Volume | |
Media Volume | 973.369 |
Capitalizzazione | 390,448M |
Beta (5 anni mensile) | 2,47 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -10,31 |
Prossima data utili | 07 mag 2024 - 13 mag 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 55,00 |
CRB-701 demonstrates a differentiated nonclinical profile relative to enfortumab vedotinEarly dose escalation clinical data supports differentiating features established pre-clinicallyThe company on schedule to initiate its US study in Q1-2024 NORWOOD, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced that a poster characterizing the pre-clinical validation of CRB-701, a next ge
NORWOOD, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that it will host a Virtual ‘Meet the Expert’ event on the development of a next generation Nectin-4 antibody drug conjugate, focusing on opportunities and challenges for CRB-701, on Tuesday, October 10, 2023 at 10:30am ET. To register for the webinar, click here. The event will feature several Oncology experts Daniel P.